Fiber2026

The impact of pectin supplementation on systemic inflammation pathways, gut microbiome, and metabolic health in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A study protocol for a randomised controlled trial.

Al-Tameemi Noor Kifah, Grove Jane I, Hoad Caroline L, Wai Jessica Wong Sun et al. — PloS one

Summary

This study will investigate whether adding pectin, a type of dietary fiber, can improve liver health, reduce inflammation, and positively change gut bacteria in people with a common liver condition called MASLD. Researchers will give pectin supplements to participants and monitor various health markers to understand its potential benefits. The findings could help develop new dietary strategies for managing this liver disease.

AI-generated summary — read the original

Key points

This study explores if pectin, a type of fiber, can help people with a common liver condition called MASLD.
Researchers will examine how pectin affects inflammation, gut bacteria, and overall metabolic health.
The findings could provide insights into new dietary approaches for managing MASLD.

What the study looked at

What question did this study ask? This research aims to understand if supplementing with pectin, a type of soluble fiber found in fruits, can improve health markers in individuals with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Specifically, it will investigate pectin's effects on inflammation throughout the body, the composition of gut bacteria, and overall metabolic health. How was it studied? This paper describes the plan for a future study. Researchers will recruit 30 adults diagnosed with MASLD and randomly assign them to one of two groups: one receiving 15 grams of low-methoxyl pectin daily, and the other receiving a placebo, for six weeks. Neither the participants nor the researchers will know who is receiving pectin. Before and after the intervention, participants will undergo various assessments, including blood tests, stool sample collection, and liver scans (FibroScan and MRI for a subset) to measure changes in liver health, inflammation, and gut microbiome. What did it find? This publication is a study protocol, meaning it outlines the detailed plan and methods for a clinical trial that has not yet been conducted. Therefore, it does not present any results or findings at this stage. The goal is to lay the groundwork for a robust study that can provide new evidence on how soluble fiber might influence the gut-liver connection and potentially lead to new dietary strategies for MASLD.

Dietary takeaway

While this study is still in the planning stages, it highlights the ongoing interest in how dietary fiber, like pectin, might support liver and metabolic health. Including a variety of fiber-rich foods such as fruits, vegetables, and whole grains in your diet is generally beneficial for gut health and overall well-being. Remember, this is just one study protocol, and more research is needed before definitive dietary recommendations can be made for specific conditions like MASLD.

Abstract

BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease, affecting over 30% of adults worldwide. Emerging evidence suggests that dietary fibre, particularly pectin, may improve metabolic health by modulating inflammation, gut microbiota composition, and intestinal permeability. However, controlled human studies in MASLD are limited. This study aims to evaluate the effect of pectin supplementation on systemic inflammation, gut microbiome, and metabolic health in patients with MASLD. METHODS: This single-centre, double-blind, randomised, placebo-controlled dietary intervention will be conducted at Nottingham University Hospitals NHS Trust in partnership with the University of Nottingham. Thirty adults with MASLD will be randomised (1:1) to receive either 15g/day Low-methoxyl (LM) pectin or a matched placebo for six weeks. Each participant will attend baseline and post-intervention visits during which anthropometric data, fasting blood samples, and stool samples will be collected. FibroScan® assessments will be performed for all participants at both visits to quantify liver stiffness and steatosis. Twenty-two participants will take part in a magnetic resonance imaging (MRI) sub-study to evaluate hepatic and intestinal characteristics at baseline and post-intervention. Laboratory analyses will include liver function, lipid, glycemic, and inflammatory markers, alongside profiling of gut microbiota composition and short-chain fatty acids. DISCUSSION: This is the first randomised controlled study to evaluate the mechanistic effects of pectin supplementation on inflammation, gut microbiome composition, and metabolic outcomes in MASLD. The results may generate novel evidence on the role of soluble fibre in modulating the gut-liver axis and support the development of scalable, nutrition-based interventions to improve metabolic and hepatic health in this population. CLINICAL TRIAL REGISTRATION: The trial was registered on ClinicalTrials.gov (Identifier: NCT07093346).

View on PubMed →DOI: 10.1371/journal.pone.0352397